Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

PHASE1UnknownINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2021

Conditions
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Interventions
DRUG

Paclitaxel

Cycle 1 = 60 mg/m\^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m\^2 IP weekly over 1 hour x 3 weeks of each cycle.

DRUG

Carboplatin

Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.

DRUG

Avastin

Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.

Trial Locations (5)

19111

Fox Chase Cancer Center, Philadelphia

21287

Johns Hopkins Hospital, Baltimore

77030

University of Texas MD Anderson Cancer Center, Houston

98109

Fred Hutchinson Cancer Research Center, Seattle

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Massachusetts General Hospital

OTHER